QUARTERLY ACTIVITIES REPORT – SEPTEMBER QUARTER 2025

“East-to-West” strategy advanced; balance sheet strengthened

Key highlights

• First “East to West” cellular immunotherapy CAR-T product now in advanced stages of licensing contract negotiation; private financing advanced

• Two “at market” placements raised $1.6 million before costs (post period end)

• Remaining balance of New Life Sciences Capital (“NLSC”) investment repaid in cash; no further shares to be issued under either NLSC [or Meurs Group] Investment Agreement[s] (post period end)